Bioventus’ (BVS) Outperform Rating Reaffirmed at Barrington Research

Bioventus (NASDAQ:BVS)‘s stock had its “outperform” rating reiterated by Barrington Research in a report issued on Friday,Benzinga reports. They presently have a $14.00 target price on the stock. Barrington Research’s price target points to a potential upside of 47.52% from the stock’s previous close.

BVS has been the subject of several other research reports. Cantor Fitzgerald upgraded shares of Bioventus to a “strong-buy” rating in a research note on Wednesday, March 4th. CJS Securities assumed coverage on shares of Bioventus in a research note on Friday, March 27th. They issued a “market outperform” rating and a $14.00 price target for the company. Finally, Craig Hallum boosted their price target on shares of Bioventus from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, March 6th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $14.00.

Bioventus Stock Down 13.3%

Bioventus stock opened at $9.49 on Friday. Bioventus has a fifty-two week low of $5.81 and a fifty-two week high of $11.25. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.13 and a current ratio of 1.69. The firm has a 50 day moving average price of $9.65 and a 200 day moving average price of $8.47. The company has a market capitalization of $792.79 million, a PE ratio of 23.15, a price-to-earnings-growth ratio of 1.39 and a beta of 0.72.

Bioventus (NASDAQ:BVS) last posted its earnings results on Wednesday, May 6th. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.06. The firm had revenue of $132.09 million during the quarter. Bioventus had a net margin of 4.94% and a return on equity of 29.97%. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. Research analysts expect that Bioventus will post 0.79 earnings per share for the current year.

Insider Activity

In other news, Director Michelle Mcmurry-Heath sold 12,000 shares of Bioventus stock in a transaction on Wednesday, March 11th. The shares were sold at an average price of $8.79, for a total transaction of $105,480.00. Following the completion of the sale, the director directly owned 44,997 shares of the company’s stock, valued at approximately $395,523.63. The trade was a 21.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 33.00% of the company’s stock.

Institutional Investors Weigh In On Bioventus

Several institutional investors have recently modified their holdings of the company. Bank of America Corp DE lifted its position in shares of Bioventus by 40.3% during the 1st quarter. Bank of America Corp DE now owns 86,057 shares of the company’s stock worth $786,000 after purchasing an additional 24,723 shares during the last quarter. Engine Capital Management LP purchased a new stake in Bioventus in the first quarter valued at $2,876,000. Quantinno Capital Management LP lifted its position in Bioventus by 119.6% in the first quarter. Quantinno Capital Management LP now owns 72,023 shares of the company’s stock valued at $658,000 after acquiring an additional 39,222 shares during the last quarter. Lazard Asset Management LLC lifted its position in Bioventus by 12.9% in the first quarter. Lazard Asset Management LLC now owns 305,517 shares of the company’s stock valued at $2,789,000 after acquiring an additional 35,008 shares during the last quarter. Finally, Sei Investments Co. lifted its position in Bioventus by 160.7% in the first quarter. Sei Investments Co. now owns 289,648 shares of the company’s stock valued at $2,644,000 after acquiring an additional 178,539 shares during the last quarter. 62.94% of the stock is owned by hedge funds and other institutional investors.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.